Corporate Integrity Agreement Novartis

DisclaimerCe press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be made with words such as “following,” “positioning,” “future,” “next generation,” “boarding,” “will,” “develop,” “expected,” “effort,” “commitment,” “expectations,” “commitments,” “engaged,” “work,” “continue to improve,” “further improve,” “transition “transition,” “additional steps” or “other steps” or through explicit or tacit discussions about future changes to peer-to-peer medical training in the United States and Novartis` agreements on additional obligations to the integrity of the U.S. Department of Inspector General`s Office of Inspector General Health – Human Services. You should not rely too much on these statements. These forward-looking statements are based on our current beliefs and expectations regarding future events and are subject to significant known and unknown risks and uncertainties. If one or more of these risks or uncertainties arise or if the underlying assumptions prove to be incorrect, actual results may differ materially from those presented in the forward-looking statements. There can be no guarantee that future changes to Novartis-sponsored medical training in the United States will be implemented within a certain time frame or even successfully, or that they will take into account some of their objectives and benefits. Nor can there be any assurance that we will successfully implement or meet the additional corporate integrity obligations agreed with the OIG. Nor can there be any guarantee regarding the reactions of health care professionals, customers, strategic partners and other stakeholders to future changes to peer-to-peer medical training in the United States, sponsored by Novartis, or to the additional corporate integrity obligations. In particular, our expectations for such changes to Novartis-sponsored medical training in the United States and additional corporate integrity obligations could be influenced, among other things, by the potential side effects of proposed changes to Novartis-sponsored medical training in the United States and by additional corporate integrity obligations by health professionals. , customers, strategic partners or other stakeholders; the potential that the expected benefits of planned changes to peer-to-peer medical training in the United States, sponsored by Novartis, may not be realized or may take longer than expected; Potential or actual breaches of additional corporate integrity obligations; regulatory action or delays or regulation of the state in general; global trends in health sector cost reduction, including large and general public pricing, pressure on reimbursements and price transparency requirements; our ability to obtain or maintain intellectual property protection; Special prescription preferences of physicians and patients general political, economic and trade conditions, including pandemic effects and efforts such as COVID-19; Safety, quality, data integrity or manufacturing issues Potential or actual data breaches or disruptions to our information technology systems, as well as other risks and factors that are indicated in Novartis AG`s current Form 20-F, which is submitted to the U.S.

Securities and Exchange Commission.

Comments are closed.